Genzyme knockback has implications for biosimilars
The problems facing companies trying to bring 'biosimilar' versions of biologic drugs to market were thrown into stark relief yesterday when the US Food and Drug Administration (FDA) refused to approve Genzyme's genetic disorder treatment Myozyme made...